Medicare GLP-1 Bridge Program Launches in July 2026 to Provide $50 Monthly Weight Loss Wegovy and Zepbound
In a major policy shift, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge program on July 1, 2026. This 18-month pilot program, scheduled to run through December 31, 2027, will provide eligible Medicare Part D beneficiaries with access to select GLP-1 weight-loss medications—specifically Wegovy and Zepbound—for a fixed monthly copay of $50.
The Medicare GLP-1 Bridge program operates under Section 402(a)(1)(A) of the Social Security Amendments of 1967. This structure allows CMS to conduct a short-term demonstration that sidesteps the 2003 Medicare Modernization Act, which legally bars standard Medicare plans from covering weight-loss drugs.
Key Operational and Financial Details
The program is structured to operate entirely outside the standard Medicare Part D benefit's coverage and payment flow. Key details include:
- No Insurer Risk: Part D plan sponsors (private insurance companies) do not carry any financial risk for these drugs and do not have to opt in to the program.
- Centralized Processing: CMS has appointed a single central processor to manage prior authorizations, claims adjudication, and direct payments to pharmacies.
- Beneficiary Cost-Sharing: The standard Part D deductible does not apply to these prescriptions. However, the $50 monthly copay will not count toward the beneficiary's True Out-of-Pocket (TrOOP) spending, and no low-income subsidy (LIS) is provided for this pilot.
- Taxpayer Exposure: The Trump administration originally attempted to test coverage through private Medicare Advantage and Part D plans, but insurers balked at the high financial exposure. Consequently, the program is funded directly by taxpayers and beneficiary copays. While the exact budget impact remains undisclosed, the program is expected to unleash billions of dollars in federal spending and millions of new patients, benefiting manufacturers Eli Lilly and Novo Nordisk.
- BALANCE Model Delayed: The Bridge program was originally designed as a transition to a broader "Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth" (BALANCE) Model in Part D. With the BALANCE model deferred, CMS extended the GLP-1 Bridge through the end of 2027 to collect more comprehensive utilization data.
Quotes
From the official CMS Medicare GLP-1 Bridge overview:
"The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027. The Medicare GLP-1 Bridge will operate outside of the Medicare Part D benefit’s coverage and payment flow."
From STAT News on the program's funding and taxpayer impact:
"The temporary coverage of obesity medications, which sidesteps federal law, will unleash millions of new patients and billions of dollars in revenue for the drugs’ manufacturers, Eli Lilly and Novo Nordisk. ... Instead, the drugs will be covered solely by taxpayers and the beneficiaries who fill prescriptions."